1. Home
  2. HLX vs CAPR Comparison

HLX vs CAPR Comparison

Compare HLX & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Helix Energy Solutions Group Inc.

HLX

Helix Energy Solutions Group Inc.

HOLD

Current Price

$8.64

Market Cap

1.4B

Sector

Energy

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

BUY

Current Price

$28.70

Market Cap

1.6B

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
HLX
CAPR
Founded
1979
2005
Country
United States
United States
Employees
N/A
231
Industry
Oilfield Services/Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.6B
IPO Year
1996
2011

Fundamental Metrics

Financial Performance
Metric
HLX
CAPR
Price
$8.64
$28.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
8
Target Price
$11.50
$44.63
AVG Volume (30 Days)
1.3M
773.2K
Earning Date
04-22-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$876,561,000.00
N/A
Revenue This Year
$2.05
N/A
Revenue Next Year
$5.46
$3.31
P/E Ratio
N/A
N/A
Revenue Growth
3.60
N/A
52 Week Low
$5.52
$4.30
52 Week High
$10.75
$40.37

Technical Indicators

Market Signals
Indicator
HLX
CAPR
Relative Strength Index (RSI) 34.57 51.22
Support Level $8.58 $27.52
Resistance Level $10.54 $30.21
Average True Range (ATR) 0.34 1.33
MACD -0.09 0.26
Stochastic Oscillator 14.08 76.59

Price Performance

Historical Comparison
HLX
CAPR

About HLX Helix Energy Solutions Group Inc.

Helix Energy Solutions Group Inc is an offshore energy services company. It provides specialty services to the offshore energy industry, with an emphasis on well intervention and robotics operations. Helix provides services in deep water in the Gulf of Mexico, Brazil, the North Sea, Asia Pacific and West Africa regions. It has four segments: Well Intervention, Robotics, Shallow Water Abandonment and Production Facilities. The Well Intervention segment includes vessels and equipment used to perform well intervention services in the Gulf of Mexico, the North Sea and Brazil. It derives the majority of its revenue from the U.S., and it also has its presence in North Sea, Brazil, Asia Pacific, West Africa, and Other.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: